Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30781
Title: Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease.
Austin Authors: Braude, Michael;Roberts, Stuart;Majeed, Ammar;Lubel, John;Prompen, Jirayut;Dev, Anouk;Sievert, William;Bloom, Stephen;Gow, Paul J ;Kemp, William
Affiliation: Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria, Australia
Gastroenterology and Hepatology, Monash Health, Clayton, Victoria, Australia
School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
Gastroenterology and Hepatology, Alfred Health, Melbourne, Victoria, Australia
Monash Central Clinical School, Monash University, Clayton, Victoria, Australia
Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia
Gastroenterology and Hepatology
Issue Date: 1-Sep-2022
metadata.dc.date: 2022
Publication information: Liver international: 2022
Abstract: Progressive liver fibrosis related to non-alcoholic fatty liver disease (NAFLD) is associated with all-cause and liver-related mortality. We assessed vibration-controlled transient elastography (VCTE) as a predictor of mortality. Data from patients who underwent VCTE for NAFLD at 4 large health services in Victoria, Australia between the years 2008 to 2019 were linked to state-wide data registries. Cause of death (COD) and predictors of all-cause mortality were subsequently analysed using descriptive statistics and Cox-proportional regression analysis. Of 7079 VCTE records submitted for data linkage, 6341 were matched via data registry linkage. There were 217 deaths over a 22,653 person-year follow-up. COD included malignancies other than hepatocellular carcinoma (HCC) (18.0%, n = 39), sepsis (16.1%, n = 35), decompensated liver disease (15.2%, n = 33), cardiac disease (15.2%, n = 33), and HCC 6.0% (n = 13). Controlled attenuation parameter (CAP) was not associated with mortality in univariable analysis (HR = 1.00, CI 1.0-1.0, p = 0.488). Mortality increased with liver stiffness measurement (LSM) (HR 1.02 per kilopascal, CI 1.01-1.03, p < 0.001), Charlson comorbidity index (CCI) (HR 1.32 for each point, CI 1.27-1.38, p <0.001), and age (HR 1.05 per annum, CI 1.03-1.07, p < 0.001) in multivariable analysis. LSM ≥ 10kPa suggestive of compensated advanced chronic liver disease (cACLD) was associated with mortality in multivariable analysis (HR 2.31, CI 1.73-3.09, p < 0.001). VCTE LSM, in addition to age and CCI, is independently associated with increased all-cause mortality in a large cohort with NAFLD.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30781
DOI: 10.1111/liv.15415
ORCID: https://orcid.org/0000-0002-6641-0032
https://orcid.org/0000-0002-9015-7997
https://orcid.org/0000-0003-1170-6757
https://orcid.org/0000-0002-0787-7273
PubMed URL: 36050821
Type: Journal Article
Subjects: Charlson comorbidity index
Non-alcoholic fatty liver disease
cause of death, registries
elasticity imaging techniques
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.